EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer

Ru M Wen, Jessica C Stark, G Edward W Marti, Zenghua Fan, Aram Lyu, Fernando Jose Garcia Marques, Xiangyue Zhang, Nicholas M Riley, Sarah M Totten, Abel Bermudez, Rosalie Nolley, Hongjuan Zhao und 5 weitere

Journal of Clinical Investigation · 16.12.2024 · 134 (24)

DOI: 10.1172/jci180282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 22.10.2024. Verfasst von Ru M Wen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Lectins. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NCRR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer is the second leading cause of male cancer death in the U.S. Current immune checkpoint inhibitor–based immunotherapies have improved survival for many malignancies; however, they have failed to prolong survival for prostate cancer. Siglecs (sialic acid–binding immunoglobulin-like lectins) are expressed on immune cells and regulate their function. Siglec-7 and Siglec-9 contribute to immune evasion in cancer by interacting with sialic acid–containing glycoprotein ligands on cancer cells. However, the role of Siglec-7/9 receptors and their ligands in prostate cancer remains poorly understood. Here, we find that Siglec-7 and Siglec-9 are associated with poor prognosis in patients with prostate cancer and are highly expressed in myeloid cells, including macrophages, in prostate tumor tissues. Siglec-7 and -9 ligands were expressed in prostate cancer cells and human prostate tumor tissues. Blocking the interactions between Siglec-7/9 and sialic acids inhibited prostate cancer xenograft growth and increased immune cell infiltration in humanized mice in vivo. Using a CRISPRi screen and mass spectrometry, we identified CD59 as a candidate Siglec-9 ligand in prostate cancer. The identification of Siglec-7 and -9 as potential therapeutic targets, including the CD59/Siglec-9 axis, opens up opportunities for immune-based interventions in prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsLectinsMaleHumansAnimalsMiceAntigens, CDAntigens, Differentiation, MyelomonocyticAntigens, Differentiation, B-LymphocyteGlycoproteinsSialic Acid Binding Immunoglobulin-like LectinsCell Line, TumorNeoplasm Proteins

Stichwörter der Autor:innen

Cancer immunotherapyImmunotherapyOncologyProstate cancer

Substanzen

SIGLEC9 protein, humanSIGLEC7 protein, humanLectinsAntigens, CDAntigens, Differentiation, MyelomonocyticAntigens, Differentiation, B-LymphocyteGlycoproteinsSialic Acid Binding Immunoglobulin-like LectinsNeoplasm Proteins

Autor:innen und Institutionen

  • Department of Urology.
  • Department of Chemistry, and Sarafan ChEM-H, Stanford University, Stanford, California, USA.
  • Department of Biological Engineering, Department of Chemical Engineering, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
  • Department of Molecular and Cellular Physiology, Stanford University, Stanford, California, USA.
  • Department of Medicine, UCSF, San Francisco, California, USA.
  • Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • NCRR NIH HHS
  • dod
  • burroughs wellcome fund
  • NIH, DoD

Zitieren

APA

Wen, R. M., Stark, J. C., Marti, G. E. W., Fan, Z., Lyu, A., Garcia Marques, F. J., Zhang, X., Riley, N. M., Totten, S. M., Bermudez, A., Nolley, R., Zhao, H., Fong, L., Engleman, E. G., Pitteri, S. J., Bertozzi, C. R., & Brooks, J. D. (2024). Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer. Journal of Clinical Investigation, 134(24). https://doi.org/10.1172/jci180282

Vancouver

Wen RM, Stark JC, Marti GEW, Fan Z, Lyu A, Garcia Marques FJ, et al. Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer. Journal of Clinical Investigation. 2024;134(24). doi:10.1172/jci180282

BibTeX
@article{Wen2024,
  author = {Wen, Ru M and Stark, Jessica C and Marti, G Edward W and Fan, Zenghua and Lyu, Aram and Garcia Marques, Fernando Jose and Zhang, Xiangyue and Riley, Nicholas M and Totten, Sarah M and Bermudez, Abel and Nolley, Rosalie and Zhao, Hongjuan and Fong, Lawrence and Engleman, Edgar G and Pitteri, Sharon J and Bertozzi, Carolyn R and Brooks, James D},
  title = {Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  volume = {134},
  number = {24},
  doi = {10.1172/jci180282}
}
Kostenlos starten →